SPDEF与恶性肿瘤关系的研究进展

doi:10.11904/j.issn.1002-3070.2020.02.018

摘要/Abstract

摘要： 含SAM尖端结构域的E26转化特异性因子(SAM pointed domain cintaining Ets transcription factor,SPDEF)是Ets转录因子家族的成员之一。SPDEF又称为前列腺源性Ets因子(Prostate-derived Ets factor,PDEF),最初在前列腺癌中发现,在前列腺癌进展过程中发挥重要作用,作为前列腺特异性抗原基因(PSA)启动子的非雄激素依赖性转录激活因子。目前研究发现SPDEF在前列腺癌、乳腺癌和肺癌等不同组织中发挥抑制肿瘤或促进肿瘤的作用,但其具体机制仍未完全阐明。本文主要介绍SPDEF的结构和SPDEF在不同肿瘤中的调控机制,预期SPDEF在肿瘤中的重要作用,为相关肿瘤的防治提供了新思路。

关键词: SPDEF, 恶性肿瘤, 调控机制

Abstract: SAM pointed domain cintaining Ets transcription factor(SPDEF)is a member of the Ets transcription factor family.SPDEF is also known as prostate-derived Ets factor(PDEF).It was originally found in prostate cancer and plays an important role in the progression of prostate cancer,acting as a prostate-specific antigen(PSA)promoter for a non-androgen-dependent transcriptional activator.Current many studies have found that SPDEF plays a role in inhibiting tumors or promoting tumors in different tissues such as prostate cancer,breast cancer and lung cancer,but the specific mechanism has not been fully elucidated.This article mainly introduces the structure of SPDEF and the regulatory mechanism of SPDEF in different tumors.The important role of SPDEF in tumors is expected to provide new ideas for the prevention and treatment of related tumors.

Key words: SPDEF, Malignant tumor, Regulatory mechanism

中图分类号:

R730.2

林玉华, 倪振华, 孙亦鹏, 毕俊杰, 王雄彪. SPDEF与恶性肿瘤关系的研究进展[J]. 实用肿瘤学杂志, 2020, 34(2): 185-188.

LIN Yuhua, NI Zhenhua, SUN Yipeng, BI Junjie, WANG Xiongbiao. Research progress on the relationship between SPDEF and malignant tumors[J]. Journal of Practical Oncology, 2020, 34(2): 185-188.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2020.02.018

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2020/V34/I2/185

参考文献

1 Oettgen P,Finger E,Sun Z,et al.PDEF,a novel prostate epithelium-specific ets transcription factor,interacts with the androgen receptor and activates prostate-specific antigen gene expression[J].J Biol Chem,2000,275(2):1216-1225.
2 He J,Pan Y,Hu J,et al.Profile of Ets gene expression in human breast carcinoma[J].Cancer Biol Ther,2007,6(1):76-82.
3 Noah TK,Kazanjian A,Whitsett J,et al.SAM pointed domain ETS factor(SPDEF)regulates terminal differentiation and maturation of intestinal goblet cells[J].Exp Cell Res,2010,316(3):452-465.
4 Wei GH,Badis G,Berger MF,et al.Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo[J].EMBO J,2010,29(13):2147-2160.
5 Oikawa T,Yamada T.Molecular biology of the Ets family of transcription factors[J].Gene,2003,303:11-34.
6 Cho JY,Lee M,Ahn JM,et al.Proteomic analysis of a PDEF Ets transcription factor-interacting protein complex[J].J Proteome Res,2009,8(3):1327-1337.
7 Situ J,Zhang H,Lu L,et al.Clinical significance of PSMA,TERT and PDEF in malignant tumors of the prostate[J].Eur Rev Med Pharmacol Sci,2017,21(15):3347-3352.
8 Cao L,Li C,Xu C,et al.Clinical significance of PDEF factor expression and its relation to androgen receptor in ER(-)breast cancer[J].Histopathology,2018,73(5):819-831.
9 Guo M,Tomoshige K,Meister M,et al.Gene signature driving invasive mucinous adenocarcinoma of the lung[J].EMBO Mol Med,2017,9(4):462-481.
10 Wu J,Qin W,Wang Y,et al.SPDEF is overexpressed in gastric cancer and triggers cell proliferation by forming a positive regulation loop with FoxM1[J].J Cell Biochem,2018,119(11):9042-9054.
11 Chen WY,Tsai YC,Yeh HL,et al.Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer[J].Sci Signal,2017,10(492):6826.
12 Lo YH,Noah TK,Chen MS,et al.SPDEF induces quiescence of colorectal cancer cells by changing the transcriptional targets of beta-catenin[J].Gastroenterology,2017,153(1):205-218.
13 Xiao B,Kuang Z,Zhang W,et al.Glutamate ionotropic receptor kainate type subunit 3(GRIK3)promotes epithelial-mesenchymal transition in breast cancer cells by regulating SPDEF/CDH1 signaling[J].Mol Carcinog,2019,58(7):1314-1323.
14 Hu H,Sun Z,Li Y,et al.The histologic classifications of lung adenocarcinomas are discriminable by unique lineage backgrounds[J].J Thorac Oncol,2016,11(12):2161-2172.
15 Steffan JJ,Koul S,Meacham RB,et al.The transcription factor SPDEF suppresses prostate tumor metastasis[J].J Biol Chem,2012,287(35):29968-29978.
16 Chen WY,Zeng T,Wen YC,et al.Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer[J].Cancer Lett,2019,440/441:35-46.
17 Tsai YC,Chen WY,Abou-Kheir W,et al.Androgen deprivation therapy-induced epithelial-mesenchymal transition of prostate cancer through downregulating SPDEF and activating CCL2[J].Biochim Biophys Acta Mol Basis Dis,2018,1864(5 Pt A):1717-1727.
18 Fararjeh AS,Liu YN.ZBTB46,SPDEF,and ETV6:Novel potential biomarkers and therapeutic targets in castration-resistant prostate cancer[J].Int J Mol Sci,2019,20(11):2802.
19 Cui X,Cui M,Asada R,et al.The androgen-induced protein AIbZIP facilitates proliferation of prostate cancer cells through downregulation of p21 expression[J].Sci Rep,2016,6:37310.
20 Tamura RE,Paccez JD,Duncan KC,et al.GADD45alpha and gamma interaction with CDK11p58 regulates SPDEF protein stability and SPDEF-mediated effects on cancer cell migration[J].Oncotarget,2016,7(12):13865-13879.
21 Wang F,Koul S,Shanmugam PST,et al.Prostate-derived Ets factor(PDEF)inhibits metastasis by inducing epithelial/luminal phenotype in prostate cancer Cells[J].Mol Cancer Res,2018,16(9):1430-1440.
22 Pal M.Tumor metastasis suppressor functions of Ets transcription factor through integrin beta3-mediated signaling pathway[J].J Cell Physiol,2019,234(11):20266-20274.
23 Noah TK,Lo YH,Price A,et al.SPDEF functions as a colorectal tumor suppressor by inhibiting beta-catenin activity[J].Gastroenterology,2013,144(5):1012-1023.
24 Mukhopadhyay A,Khoury T,Stein L,et al.Prostate derived Ets transcription factor and Carcinoembryonic antigen related cell adhesion molecule 6 constitute a highly active oncogenic axis in breast cancer[J].Oncotarget,2013,4(4):610-621.
25 Cao L,Xu C,Xiang G,et al.AR-PDEF pathway promotes tumour proliferation and upregulates MYC-mediated gene transcription by promoting MAD1 degradation in ER-negative breast cancer[J].Mol Cancer,2018,17(1):136.
26 Shirkavand A,Boroujeni ZN,Aleyasin SA.Examination of methylation changes of VIM,CXCR4,DOK7,and SPDEF genes in peripheral blood DNA in breast cancer patients[J].Indian J Cancer,2018,55(4):366-371.
27 Hsu YL,Hung JY,Lee YL,et al.Identification of novel gene expression signature in lung adenocarcinoma by using next-generation sequencing data and bioinformatics analysis[J].Oncotarget,2017,8(62):104831-104854.
28 Sumardika IW,Chen Y,Tomonobu N,et al.Neuroplastin-beta mediates S100A8/A9-induced lung cancer disseminative progression[J].Mol Carcinog,2019,58(6):980-995.
29 王晓赟.UCA1-miR-204-SPDEF轴在胃癌发生中的作用[D].济南:山东大学,2019.
30 Zhang YQ,Pei JH,Shi SS,et al.CRISPR/Cas9-mediated knockout of the PDEF gene inhibits migration and invasion of human gastric cancer AGS cells[J].Biomed Pharmacother,2019,111:76-85.
31 Khan MI,Debski KJ,Dabrowski M,et al.Gene set enrichment analysis and ingenuity pathway analysis of metastatic clear cell renal cell carcinoma cell line[J].Am J Physiol Renal Physiol,2016,311(2):424-436.
32 Chen EB,Zhou SL,Pang XG,et al.Prostate-derived ETS factor improves prognosis and represses proliferation and invasion in hepatocellular carcinoma[J].Oncotarget,2017,8(32):52488-52500.
33 Tsui KH,Lin YH,Chung LC,et al.Prostate-derived ets factor represses tumorigenesis and modulates epithelial-to-mesenchymal transition in bladder carcinoma cells[J].Cancer Lett,2016,375(1):142-151.
34 Steffan JJ,Koul HK.Prostate derived ETS factor(PDEF):a putative tumor metastasis suppressor[J].Cancer Lett,2011,310(1):109-117.
35 Sood AK,Kim H,Geradts J.PDEF in prostate cancer[J].Prostate,2012,72(6):592-596.

[1]	孙坤, 王冲, 沈成凤, 张爽, 张辉, 宋桂德, 王卓, 王德征. 2015年天津市恶性肿瘤流行情况分析[J]. 实用肿瘤学杂志, 2020, 34(2): 114-119.
[2]	包乐, 唐丽萍. EphB6受体在恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2020, 34(1): 83-87.
[3]	李亚飞, 张霄, 王雪飞, 翁明娇, 王天真. RNA结合蛋白Lin28在恶性肿瘤发生发展中的作用和分子机制[J]. 实用肿瘤学杂志, 2019, 33(5): 456-460.
[4]	陈宏博, 余增荣, 丁小凡肖林. 盆腔肿瘤IMRT下骨髓剂量-体积参数与急性血液学毒性相关性研究进展[J]. 实用肿瘤学杂志, 2019, 33(4): 361-366.
[5]	赵金璐, 李国东刘明. 长链非编码RNA CCAT1与消化系统恶性肿瘤关系的研究进展[J]. 实用肿瘤学杂志, 2019, 33(4): 367-370.
[6]	张茂祥,孙惠昕,宋冰冰. 2008—2012年哈尔滨市道里区恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2019, 33(3): 261-265.
[7]	李诚, 兰莉, 杨超, 张婷婷, 王蕊, 林琳, 田文静. 2015—2017年哈尔滨市恶性肿瘤发病与死亡特征分析[J]. 实用肿瘤学杂志, 2019, 33(1): 62-66.
[8]	韩滕综述, 唐丽萍审校. PD-L1的表达与妇科恶性肿瘤预后关系的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 468-470.
[9]	韩帮岭, 汪亦民, 薛英威. 中性粒细胞与恶性肿瘤关系的研究进展[J]. 实用肿瘤学杂志, 2018, 32(4): 349-352.
[10]	周洁, 陈钰(综述), 陈道桢(审校). 纳米材料在肿瘤光动力治疗中的应用[J]. 实用肿瘤学杂志, 2018, 32(3): 245-249.
[11]	侯思宇(综述), 陈秀玮(审校). JMJD2B蛋白结构功能及在恶性肿瘤发生发展中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(3): 250-253.
[12]	张婷, 侯光营, 王鑫(综述), 贺岩(审校). QKI蛋白在恶性肿瘤中的研究进展及临床意义[J]. 实用肿瘤学杂志, 2018, 32(3): 263-266.
[13]	纪巧, 陈丽(综述), 何远桥(审校). 三维组织药敏法在肿瘤个体化精准医疗中的应用[J]. 实用肿瘤学杂志, 2018, 32(3): 280-284.
[14]	李静,张云艳. miR-331-3p在恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(2): 125-129.
[15]	张永欣, 黄河. Galectin-9与多种恶性肿瘤的研究进展及作用机制探讨[J]. 实用肿瘤学杂志, 2018, 32(2): 159-163.